| Document |
Document Title |
|
WO/2017/034420A1 |
Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, ...
|
|
WO/2017/033170A1 |
The present disclosure relates to a hydrophilic composition, namely a solution comprising at least one phosphodiesterase 5 inhibitor and micronised particles of hyaluronic acid, with mucoadhesion properties and transmucosal transport/car...
|
|
WO/2017/029271A1 |
The present invention relates to lysobactin for use in the treatment of bovine mastitis.
|
|
WO/2017/028025A1 |
Disclosed is a use of a mussel adhesive protein or a preparation thereof for inhibiting a mucosal inflammation. The mucosal inflammation comprises oral mucositis, rhinitis, otitis media, conjunctivitis, pharyngitis, laryngitis, tracheiti...
|
|
WO/2017/031416A1 |
Provided are methods for prophylaxis and/or therapy for a disorder correlated with Brd4 function in brain neurons. The method involves administering to an individual in need thereof a therapeutically effective amount of a Bromodomain and...
|
|
WO/2017/028026A1 |
Disclosed is a use of a mussel adhesive protein or a preparation thereof for mucosal protection, comprising: protecting mucosa from damage caused by ultraviolet, radiation, a high- and low-temperature object, seawater, environmental poll...
|
|
WO/2017/024029A1 |
Technologies are described for formulations and methods to produce a topical formulation. Topical formulations may comprise a β-carboline compound. The β-carboline compound may be in particulate form. The particle size of the particula...
|
|
WO/2017/021435A1 |
The present invention relates to new compounds useful as antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55), and in particular to their use as a non-hormonal male contraceptive. The present invention also relates t...
|
|
WO/2017/022095A1 |
[Problem] To promote impregnation in artificial insemination of livestock, provided are an impregnation promoting agent, which is capable of bringing environment for female livestock under artificial insemination closer to natural insemi...
|
|
WO/2017/017511A1 |
A modified release pharmaceutical composition for treating premature ejaculation. The above composition comprises full quantitative timely release (FQTR)of therapeutically effective amounts of active compounds comprising tramadol, rabepr...
|
|
WO/2017/019828A1 |
Disclosed is a compound of Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein one R3 is H and the other R3 is an aryl group substituted with zero to 3 R3a; and R1, R2, and R3a a...
|
|
WO/2017/019213A1 |
A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of hot flashes in a female subject, such as experiencing symptoms of perimenopause. The composition includes a phytoestrogen and lycop...
|
|
WO/2017/015334A1 |
Disclosed are methods of diagnosing and treating endometriosis, and in particular, endometriosis-associated infertility.
|
|
WO/2017/014315A1 |
Provided is an EP2 agonist having a high safety. A compound represented by general formula (I) (wherein each symbol is as defined in the description), a salt thereof, an N-oxide derivative thereof, a solvate of the same or a prodrug of t...
|
|
WO/2017/014312A1 |
Provided is an agent for treating/improving female hormone-dependent proliferative diseases containing a low-molecular peptide, especially an erythropoietin mimetic peptide (EMP), in particular EMP9, having an erythropoietin receptor ant...
|
|
WO/2017/014170A1 |
Provided are: a heterocyclic compound which has an HDAC-inhibiting activity and is useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancer, central nervous system diseases including...
|
|
WO2017008737A1 |
Disclosed is a natural medicinal composition for treating involutional melancholia and atypical depressive disorder and use thereof. The formulation of the composition consists in mass percentage of 70%-97.5% sea buckthorn fruit oil and ...
|
|
WO/2017/009472A1 |
The present invention relates to the use of amitriptyline as an inhibitor of connexin hemichannels (HC) in the Central Nervous System (CNS). This HC-blocking agent is advantageously used to treat disorders involving misregulated HC (nota...
|
|
WO2017010515A1 |
[Problem] To provide a therapeutic agent for estrogen-dependent gynecological disorders such as endometriosis, uterine fibroids, and adenomyosis. [Solution] An estrogen receptor α-inhibiting β partial agonist represented by structural ...
|
|
WO/2017/010856A1 |
The invention relates to veterinary medicine and biotechnology, especially with new, natural composition development for the treatment of subclinical mastitis in cows. The aim of invention is to create the effective compositions for the ...
|
|
WO/2017/000082A1 |
Applications of Levonorgestrel in the preparation of products for resisting against ovarian cancer. Applications of Levonorgestrel in the preparation of products for prohibiting proliferation of ovarian cancer cells.
|
|
WO/2017/000270A1 |
The present invention relates to a crystal form A and a crystal form B of sertraline citrate, and preparation methods therefor. The crystal form A and the crystal form B of sertraline citrate have good dissolvability, high dissolution an...
|
|
WO/2017/000080A1 |
Applications of Estrone in the preparation of products for resisting against ovarian cancer and/or breast cancer. Applications of Estrone in the preparation of products for prohibiting proliferations of ovarian cancer cells and breast ca...
|
|
WO/2017/001979A1 |
A composition comprising a dinidolyl methane compound and a cyclooligosaccharide. In addition, a formulation of such a composition as well as to the use of such composition or formulation to treat genital warts and/or neoplastic diseases...
|
|
WO/2017/002865A1 |
Provided is a core-shell structure having high cutaneous permeability. This core-shell structure is provided with a core part containing a hydrophilic drug having a molecular weight of 400 or higher, and a shell part containing a surfact...
|
|
WO/2016/206097A1 |
Disclosed are a compound represented by general formula (I) as a phosphodiesterase type-5 inhibitor or pharmaceutically acceptable salt thereof and use thereof in treating and/or preventing diseases or disease states related to the phosp...
|
|
WO/2016/207298A1 |
Drospirenone as the sole contraceptive ingredient comprised in a daily active dosage unit in an amount of at least 3 mg for use as a contraceptive for a female patient affected with obesity.
|
|
WO/2016/174155A9 |
The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a SGLT2 inhib...
|
|
WO/2016/207204A1 |
The invention relates to compounds in particular N,N-dimethyl acetamide and 1-vinyl-2- pyrrolidone, for use in a method for prevention or treatment of a disease that can be modulated or ameliorated by the inhibition of bromodomain contai...
|
|
WO/2016/204169A1 |
Provided is a therapeutic agent for peracute or acute mastitis during bovine lactation which contains, as an active ingredient, lactoferrin and which is used by way of direct injection into the affected udder through the teat canal, mult...
|
|
WO/2016/205539A1 |
Disclosed herein are methods of inducing sperm deformation. In certain embodiments, the method includes contacting a sperm with an effective amount of triptonide, thereby inhibiting sperm motility. Also disclosed herein are methods of co...
|
|
WO/2016/197878A1 |
Pharmaceutical composition for the treatment of menopausal syndrome and preparation method thereof, said composition consists of the following weight parts of herbs: Ramulus Cinnamomi 1-3, Rhizoma Zingiberis 0.5-2, Fructus Schisandrae Ch...
|
|
WO/2016/198048A2 |
The invention relates to an application of omega-3 and/or omega-6 fatty acid(s) for the therapeutic treatment of the human or animal body in the case of an impaired sphingolipid metabolism, in particular in the case of impaired sphingoli...
|
|
WO/2016/192657A1 |
The invention relates to substituted piperazine compounds and methods of use and uses thereof, and further to the pharmaceutical compositions comprising the compounds and uses thereof, wherein the compound has Formula (I) or a stereoisom...
|
|
WO/2016/190785A1 |
The invention relates to the field of medicine and concerns an agent that stimulates tissue regeneration and the recovery of diminished tissue and organ function. A medicinal agent for the treatment and/or prophylaxis of a pathological c...
|
|
WO/2016/184863A1 |
The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pe
ntafluoroethyl)estra-4,9-dien-3-one for the treatment and/or prop...
|
|
WO/2016/187269A1 |
Compositions and methods for the delivery of progestin hormones that have binding affinity to the Sex Hormone Binding Globulin (SHBG) are disclosed. The compositions combine such progestins with non-progestin SHBG ligands to displace at ...
|
|
WO/2016/183908A1 |
A traditional Chinese medicine composition for O2O offline conditioning and treatment for menstruation diarrhea, and a preparation method therefor. The traditional Chinese medicine composition is prepared by using the following component...
|
|
WO/2016/183783A1 |
Provided is a traditional Chinese medicine for treating hyperplasia of mammary glands. The traditional Chinese medicine is prepared from the following raw medicinal materials in parts by weight: 15 parts of Chinese radish seeds, 15 parts...
|
|
WO/2016/181349A1 |
Combinations of the 3-(5-fluoro-1H-indol-3-yl)pyrrolididine-2,5-dione compound with selected anti-cancer or anti-viral agents are provided. Also provided are use of these combinations for the treatment and/or prevention of cancer and end...
|
|
WO/2016/181348A1 |
Combinations of the 3-(5-fluoro-1H-indol-3-yl)pyrrolididine-2,5-dione compound with an anti-PD1 antibody or anti-PD-L1 antibody as selected anti-cancer or anti-viral agents are provided. Also provided are use of these combinations for th...
|
|
WO/2016/173435A1 |
Disclosed are a use of a pyrroloquinoline quinone (PQQ), derivative and/or salt thereof in the preparation of drugs for the treatment and/or prevention of adenomyosis, ovarian chocolate cysts and deep infiltrating endometriosis and other...
|
|
WO/2016/165770A1 |
The present invention refers to a 4-phenylbutyric acid derivative of Formula (1), wherein Y is selected from 0 or H2; R1 is selected from N2 or H; R2 is a radical of an amino acid, a salicylic acid, a 4- phenylbutyric acid, a catechol, o...
|
|
WO/2016/166186A1 |
The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine- pyrazolines of general formula (I), wherein R1, R...
|
|
WO/2016/167254A1 |
Disclosed are a restorative tonic including bee larvae, a sexual-function-improving agent including bee larvae, a male-menopausal-symptom-improving agent including bee larvae, and an anti-fatigue agent including bee larvae.
|
|
WO/2016/163400A1 |
The present invention relates to: a hot flash-suppressing agent and an ameliorating agent for menopause, each of which contains α-lactalbumin as an active ingredient; and a food or beverage and a medicine each for suppressing hot flashes.
|
|
WO/2016/160881A1 |
Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and...
|
|
WO/2016/157131A1 |
Abstract: Methods are described for improving sexual health by administering a composition in an effective amount to a subject in need thereof. More particularly, methods are described for improving sexual health by administering a macro...
|
|
WO/2016/156396A1 |
Diphenethylamine derivatives for use as highly active analgesics, diuretics, anxiolytics, for the treatment of neurodegenerative, psychiatric and neuropsychiatric disorders, and also as anti- itch, anti-addiction, anti-inflammatory, anti...
|
|
WO/2016/156990A1 |
The present invention relates to a method for increasing the embryo implantation rate in a mammalian uterus, by administering to the uterus of a mammal an effective amount of an extracellular matrix remodeling enzyme, as well as to a pro...
|
